Oncology

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Alcohol could cause 7100 annual cancer deaths by 2035.

Blood test helps predict how aggressive lung cancer patients will respond to treatment.

Top news of the day from across the health care landscape.

Switching Tasigna elicited a long-term response rate in patients with leukemia even after discontinuing treatment.

Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.

A newly created tool can diagnose cachexia in patients with cancer and other diseases.

Interim findings further support the efficacy, safety, and tolerability of Abraxane in NSCLC.

Abraxane shows promise in hard-to-treat non-small cell lung cancer patients.

Individuals with a history of cigarette smoking may benefit from regular ibuprofen use.

Top news of the day from across the health care landscape.

Once-daily tablet for hepatitis C virus contains sofosbuvir, velpatasvir, and voxilaprevir.

Checkpoint inhibitor resistance remains an issue in cancer therapy.

Top news of the week in oncology and cancer drug development.

A Memorial Sloan-Kettering pharmacist discusses the often complicated reimbursement process for oncology medications and appeals.

A hematology/oncology clinical pharmacist with Memorial Sloan-Kettering Cancer Center discusses the importance of early collaboration between pharmacists and oncologists in patient care.

Inhibiting communication between proteins and the Golgi apparatus could possibly prevent lung cancer metastasis.

Disrupting the body’s circadian clock can increase the risk of serious diseases, such as cancer.

Myeloma Genome Project to create the largest dataset of molecular profiling for patients with multiple myeloma.

In a phase 3 trial, Gazyva showed superior progression-free survival in previously untreated follicular lymphoma.

Research suggests cancer cells may evade treatment by eating adult stem cells.

Gazyva is an engineered monoclonal antibody designed to attach to CD20.

TIP60 levels could serve as a prognostic marker of breast cancer progression.

An investigational drug was found to reverse the activity of immune suppressor cells.

Top news of the day from across the health care landscape.

A modified retrovirus may hold the key to successful gene therapy for patients with a serious immune system disorder.

The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) found to be active and safe in relapsed/refractory classical Hodgkin lymphoma.

Roche’s bevacizumab (Avastin) granted expanded indication for platinum-sensitive recurrent ovarian cancer.